Additionally, exosomal miR-222 is capable of conferring drug resistance to carboplatin [66], cisplatin, or docetaxel in breast cancer cells [67], and may promote adriamycin resistance in these cells via the PTEN/Akt/p27kip1 pathway [68]. The gene discussed is CDKN1B; the disease is breast carcinoma.